Results 31 to 40 of about 6,578,993 (340)

Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

American journal of hematology/oncology, 2020
Multiple myeloma accounts for approximately 10% of hematologic malignancies.
S. Rajkumar
semanticscholar   +1 more source

Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group.

The Lancet Oncology, 2021
In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of multiple myeloma-related bone disease.
E. Terpos, E. Zamagni, S. Lentzsch, M. Drake, R. García-Sanz, N. Abildgaard, I. Ntanasis‐Stathopoulos, F. Schjesvold, J. de la Rubia, C. Kyriakou, J. Hillengass, S. Zweegman, M. Cavo, P. Moreau, J. San-Miguel, M. Dimopoulos, N. Munshi, B. Durie, N. Raje   +18 more
semanticscholar   +1 more source

Risk of Venous Thromboembolism in Multiple Myeloma Patients During the Immediate Peri-Autologous Hematopoietic Cell Transplantation Phase

Clinical and Applied Thrombosis/Hemostasis, 2023
Venous thromboembolism (VTE) is a serious complication commonly experienced in cancer patients. Incidence of VTE typically brings poor prognosis as it represents the second most common cause of mortality in cancer patients just after the malignancy ...
Hussein Awada MD, Adel Hajj Ali MD, Faiz Anwer MD, Raza Shahzad MD, Sandra Mazzoni DO, Louis Williams MD, Chakra Chaulagain MD, Betty Hamilton MD, Craig Sauter MD, Jack Khouri MD   +9 more
doaj   +1 more source

Bone Disease in Multiple Myeloma: Biologic and Clinical Implications

Cells, 2022
Multiple Myeloma (MM) is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells localized within the bone marrow. Bone disease with associated osteolytic lesions is a hallmark of MM and develops in the majority of MM ...
Zachary S. Bernstein, E. Bridget Kim, Noopur Raje   +2 more
doaj   +1 more source

Bidirectional Notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma [PDF]

, 2016
In multiple myeloma, an overabundance of monoclonal plasma cells in the bone marrow induces localized osteolytic lesions that rarely heal due to increased bone resorption and suppressed bone formation. Matrix-embedded osteocytes comprise more than 95% of
Anderson, Judith, Bellido, Teresita, Carlesso, Nadia, Chirgwin, John M., Cregor, Meloney D., Delgado-Calle, Jesus, Hiasa, Masahiro, Mohammad, Khalid S., Plotkin, Lilian I., Roodman, G. David, Yoneda, Toshiyuki   +10 more
core   +2 more sources

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma

Antibodies, 2017
2015 was a groundbreaking year for the multiple myeloma community partly due to the breakthrough approval of the first two monoclonal antibodies in the treatment for patients with relapsed and refractory disease. Despite early disappointments, monoclonal
Shih-Feng Cho, Liang Lin, Lijie Xing, Tengteng Yu, Kenneth Wen, Kenneth C. Anderson, Yu-Tzu Tai   +6 more
doaj   +1 more source

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.

The Lancet Oncology, 2021
This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma.
P. Moreau, Shaji K. Kumar, J. S. San Miguel, F. Davies, E. Zamagni, N. Bahlis, H. Ludwig, J. Mikhael, E. Terpos, F. Schjesvold, T. Martin, K. Yong, B. Durie, T. Facon, A. Jurczyszyn, S. Sidana, N. Raje, N. V. D. van de Donk, S. Lonial, M. Cavo, S. Kristinsson, S. Lentzsch, R. Hájek, K. Anderson, C. João, H. Einsele, P. Sonneveld, M. Engelhardt, R. Fonseca, A. Vangsted, K. Weisel, R. Baz, V. Hungria, J. Berdeja, F. Leal da Costa, Â. Maiolino, A. Waage, D. Vesole, E. Ocio, H. Quach, C. Driessen, J. Bladé, X. Leleu, E. Riva, P. Bergsagel, J. Hou, W. Chng, U. Mellqvist, D. Dytfeld, J. Harousseau, H. Goldschmidt, J. Laubach, N. Munshi, F. Gay, M. Beksaç, L. Costa, M. Kaiser, P. Hari, M. Boccadoro, S. Usmani, S. Zweegman, S. Holstein, O. Sezer, Simon Harrison, H. Nahi, G. Cook, M. Mateos, S. Rajkumar, M. Dimopoulos, P. Richardson   +69 more
semanticscholar   +1 more source

Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma [PDF]

, 2012
Copyright @ 2013 Macmillan Publishers Limited. This is the author's accepted manuscript. The final published article is available from the link below.Regulation of cell survival is a key part of the pathogenesis of multiple myeloma (MM).
A Barbarulo, A Chaidos, A Karadimitris, A Rahemtulla, AJ Bardwell, C Bubici, C-H Yoon, CG Pham, CR Geest, D Chauhan, D O Haskard, E Spanoudakis, EF Wagner, F Bost, F Zazzeroni, F Zhan, F Zhan, G Franzoso, H Ke, H Ke, J Cui, J Cui, J Ford, J Liu, K Kim, K Naresh, K Pruitt, K Sabapathy, KC Anderson, KN Naresh, L Aravind, L Hui, LC Platanias, M Anbalagan, M Blonska, M Gururajan, M Hallek, M Raman, M Wiznerowicz, MA Bogoyevitch, MA Bogoyevitch, MS Raab, N Chen, NJ Kennedy, NN Gangopadhyay, RT Nitta, S Goenka, S Goenka, S Papa, S Papa, SH Cho, SH Cho, SU Ahmed, SV Rajkumar, T Hideshima, T Hideshima, T Hideshima, T Kajiguchi, T Yanagawa, TE Witzig, V Brune, V Iansante, V Schreiber, YM Yang   +63 more
core   +2 more sources

Multiple myeloma

Annals of Oncology, 2010
Multiple myeloma (MM) is the second most common hematological malignancy, with an incidence of 6/100,000 in Europe. Interactions between myeloma cells and the microenvironment are essential for MM cell survival. Better knowledge of disease biology has led to the introduction of novel agents for the management of myeloma patients.
Dimopoulos, M. A., Terpos, E.
openaire   +5 more sources

Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation

Haematologica, 2018
Allogeneic stem cell transplantation is a therapeutic option under dispute but nonetheless chosen with increasing frequency for patients suffering from multiple myeloma in Europe.
Jennifer Mosebach, Sofia Shah, Stefan Delorme, Thomas Hielscher, Hartmut Goldschmidt, Heinz-Peter Schlemmer, Stefan Schönland, Ute Hegenbart, Jens Hillengass   +8 more
doaj   +1 more source